SLC2A1 and malignant endocrine neoplasm: High levels of Glut1 are characteristic of endocrine cancers including thyroid carcinomas, pancreatic and high grade serous ovarian cancers where inhibition of Glut1 impeded glycolysis mediated cancer progression (26, 38, 46).